if the clinical data is solid, this will cause a jump in SP prior to buyout. Further to that, if there are multiple interested parties, this may increase the SP further prior to buyout.
the stats of premium to buyouts, while handy, don't give you the whole picture. If the SP jumps on first offer, this isn't considered in the buyout premium. If multiple parties want in, then it's game on.
https://www.fiercebiotech.com/biotech/how-do-you-get-acquired-by-gilead-forty-seven-explains
CU6 - Media and Industry News, page-546
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.20 |
Change
0.190(2.71%) |
Mkt cap ! $2.305B | |||
| Open | High | Low | Value | Volume |
| $7.12 | $7.34 | $6.95 | $5.698M | 788.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 16776 | $7.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.27 | 197 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |